

Date: July 21, 2026

To,
BSE Limited,
20th Floor, P.J. Towers,
Dalal Street,
Mumbai - 400001.
BSE Scrip Code: 544449

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051
NSE Scrip Symbol: ANTHEM

Subject: Earnings Call Presentation of the Company Pertaining to the quarter ended June 30, 2026

Dear Sir/Ma'am

In continuation with the Company's letter dated July 15, 2026, pertaining to intimation of schedule of earnings call to be held on Wednesday, July 22, 2026, at 11:30 AM (IST) and pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the earnings presentation on the Unaudited Consolidated Financial Results of the Company for the quarter ended June 30, 2026.

The same is also available on the Company's website at <https://anthembio.com/>.

We request you to kindly take the same on record.

Thanking you,

Yours truly,
For Anthem Biosciences Limited
(Formerly known as Anthem Biosciences Private Limited)

Divya Prasad
Company Secretary & Compliance Officer
Membership No: A41438



Anthem Biosciences Limited

Investor Presentation

July 21, 2026

Safe Harbour







Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", "seek to", "future", "objective", "goal", "likely", "project", "should", "potential", "will pursue", and similar expressions of such expressions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.



Consolidated Profit & Loss Statement: Q1FY27 vs Q1FY26 vs Q4FY26 Performance

Particulars (₹ Mn)	Q1FY27	Q1FY26	YoY	Q4FY26	QoQ	FY26
Revenue from Operations	4,182	5,402	-22.6%	6,109	-31.5%	21,243
<i>CRDMO</i>	3,408	4,527	-24.7%	5,128	-33.5%	17,727
<i>Specialty Ingredients</i>	774	875	-11.5%	981	-21.1%	3,516
Other Income	249	228	9.2%	512	-51.4%	1,558
Total Revenues	4,431	5,630	-21.3%	6,622	-33.1%	22,801
Cost of materials consumed and changes in inventories	1,462	2,309	-36.7%	2,155	-32.2%	8,123
Employee benefits expense	788	720	9.5%	725	8.7%	2,827
Other expenses	426	458	-7.0%	558	-23.6%	1,955
EBITDA	1,755	2,143	-18.1%	3,184	-44.9%	9,896
EBITDA Margins	39.6%	38.1%	153 bps	48.1%	(849 bps)	43.4%
Finance cost	9	16	-44.5%	19	-53.3%	69
Depreciation and amortization expense	300	264	13.6%	396	-24.3%	1,341
PBT before exceptional items	1,446	1,862	-22.4%	2,769	-47.8%	8,486
Exceptional Items*	<i>n.a.</i>	<i>n.a.</i>	<i>n.a.</i>	(10)	<i>n.a.</i>	244
PBT after exceptional items	1,446	1,862	-22.4%	2,779	-48.0%	8,242
Total tax expense	246	505	-51.2%	882	-72.1%	2,324
Profit after tax	1,199	1,358	-11.7%	1,898	-36.8%	5,918

Q1FY27 Consolidated Financial Highlights



Note:

- EBITDA for Q1FY27 includes Other Income of INR 249 Mn (Other Operating Income o/a of forex gain (net) and RoDTEP incentive is INR 13 Mn and Financial / Non Operating Income is INR 236 Mn). Corresponding figures for Q1FY26 was Other Income of INR 228 Mn (Other Operating Income o/a of forex gain (net) and RoDTEP incentive was INR 37 Mn and Financial / Non Operating Income was INR 191 Mn)

Margin profile continues to remain strong for Q1FY27

 Strong Business Performance	₹4,182 Mn Q1FY27 Revenues	39.6% Q1FY27 EBITDA Margin	27.1% Q1FY27 PAT Margin
 Robust Technology and Infrastructure	14 + 10 Commercial + Late Stage (Phase III) Molecules	425KL Custom Synthesis Capacity	142KL Fermentation Capacity
 Strong Returns and Balance Sheet	15.4% / 23.3% ROE / Q1FY27 Post Tax ROCE	1.10x Q1FY27 Gross Fixed Assets Turnover	2.45x Net Cash / Q1FY27 EBITDA*

*Based on Annualised EBITDA

Financial Highlights: Q1FY27

Quarter Performance:

- Consolidated Revenue from Operations was ₹4,182 Mn for the quarter
 - CRDMO business delivered ₹3,408 Mn revenues
 - Specialty Ingredients delivered ₹774 Mn revenues
- EBITDA was ₹1,755 Mn, with EBITDA margins at 39.6%
- PAT (Profit After Tax) was ₹1,199 Mn, with PAT margins at 27.1%
- Net Cash position as of June 30, 2026 is ₹17,197 Mn

Message from Chairman, MD and CEO



AJAY BHARDWAJ
Chairman, MD & CEO

“Our Q1FY27 quarterly results reflect timing shifts in deliveries to key customers. The underlying demand remains strong, and with a higher concentration of scheduled deliveries in the latter half of the year, we are positioned to capture that momentum. We remain firmly committed to sustaining revenue growth aligned with our long-term historical performance.

On the margin front, we delivered year-on-year improvement across both EBITDA and PAT margins. Our disciplined focus on cost efficiencies, yield optimisation, and employee productivity continues to reinforce our industry-leading margin profile, positioning us to sustain this performance through the year”.



Thank You

Anthem Biosciences Limited

Unit I: No.49, F1 &F2, Canara Bank Road,
Bommasandra Industrial Area Phase 1,
Bommasandra, Bangalore, 560 099, India

Unit II: Plot No 276-P & 277-P, Survey No-20,
Harohalli Industrial Area, Phase II,
Near Bannikuppe Village, Kanakapura
Taluk, Ramnagar District,
Harohalli, Karnataka 562112, India

NeoAnthem Lifesciences Private Limited

Unit III: 313-P,314-P, 318-P, Harohalli
Industrial Area, Phase II,
Kanakapura Taluk, Ramnagar District,
Harohalli, Karnataka, 562112, India

For further information please contact
investors.abl@anthembio.com or anthem@adfactorspr.com